New research reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end traditional lifestyle regimens.
Published data in a major medical journal shows that while overweight people often shed about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People buying these treatments need to be cognizant of the risk of rapid rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
Such speed of regain means a return to starting weight within about 18 months.
Weighing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of these new drugs with conventional dieting.
The team point out that individuals who lose weight through dieting generally have a slower weight regain—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts suggest the way of the injections is key to understanding the heightened regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, given the high risk of weight regain, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who say that the results "highlight the long-term nature of excess weight," akin to managing diseases like hypertension.
User Testimonies
People who have come off the jabs explain a sudden return of cravings.
"It was like a trigger activating and you're instantly extremely hungry," recalled a patient.
This challenge is worsened if users have not adopted permanent lifestyle or habit modifications during treatment.
Widespread Interest
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle management.
